• University of Maryland School of Law, J.D.
  • University of Maryland, College Park, B.S. Molecular Biology and Genetics


  • District of Columbia
  • Maryland
  • U.S. Patent and Trademark Office (USPTO)

Shannon Lentz


Shannon M. Lentz is a counsel in the Intellectual Property Group in the firm's Washington, D.C. office. Her practice includes all aspects of patent law, including preparing and prosecuting patent applications; providing infringement and validity opinions; counseling in litigation and post-grant proceedings; and participating in inter partes review proceedings.

Shannon has experience with a wide range of biomedical and chemical technologies, including cell and molecular biology, genetics, organic chemistry, pharmaceutical chemistry, polymer chemistry, metallurgy, medical devices, biologics, coatings, adhesives, nanomaterials, research tools, and drug delivery technologies.

Prior to becoming an attorney, Shannon worked in the Functional Genomics group of the Biological Defense Research Directorate of the Naval Medical Research Center.


Admitted to practice: District of Columbia, Maryland, U.S. Patent and Trademark Office (USPTO).

Representative Matters

  • Representing LifeNet Health in a five-patent case against Surgalign (f/k/a RTI Surgical) involving soft tissue grafts and spinal implants, successfully defending LifeNet Health’s patents against IPR petitions filed by Surgalign.
  • Represented inventors in a highly contested patent inventorship bench trial in the Central District of California and subsequent appeal to the Federal Circuit involving a pharmaceutical compound.
  • Moderna v. CureVac: Represented patent owner CureVac in inter partes review before the PTAB relating to purification of RNA.
  • Apotex v. Amgen, IPR2016-01542 (PTAB): Represented petitioner Apotex in an inter partes review successfully invalidating a patent relating to Neupogen® and Neulasta®.
  • LifeNet Health v. Life Cell Corp., No. 2:13-cv-00486 (E.D. Virginia): Represented plaintiff LifeNet in patent-infringement action involving soft-tissue grafts. Jury awarded LifeNet over $34 million; decision affirmed on appeal. 
  • Represented university system in patent license dispute over cancer treatment in which the plaintiff pharmaceutical company sought damages exceeding $200 million. Obtained summary adjudication in favor of client.
  • Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville, Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.


Client Alerts & Newsletters

Press Coverage

Firm News & Announcements

January 27, 2022 LITIGATION NOTE: Crowell & Moring Secures Preliminary Injunction for Lonza in Ground-Breaking Cell Therapy Patent Infringement Case
January 9, 2017 Crowell & Moring Elects Six New Partners and Promotes 19 Associates to Counsel
December 16, 2016 Litigation Note: Supreme Court of California Denies Appeal in Medivation, Inc. v. Aragon Pharmaceuticals